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Abstract 
 
Introduction: The availability of non-vitamin K antagonist oral anti-coagulants alongside 
vitamin K antagonists has offered a variety of options for anti-coagulation, but has also 
necessitated a good understanding of the pharmacological properties of each of these drugs 
prior to their use, to maximise the therapeutic benefit and minimise patient harm 
 
Areas covered: This review article outlines the pharmacokinetic and pharmacodynamic 
profiles of the currently licensed NOACs and VKAs that are most commonly used in clinical 
practice, with the aim of demonstrating how variations in these processes contribute to 
their use in clinical practice. A literature search was conducted on PubMed using keywords 
and relevant articles published by the 31st of December 2018 were included.  
  
Expert opinion: The effect of a drug is determined by a combination of elements which 
include patient characteristics and external influences, in addition to its pharmacokinetic 
and pharmacodynamic properties. A good understanding of this is essential. Despite the 
wealth of information available, particularly on VKAs, our knowledge on the pharmacology 
responsible for certain drug effects and inter-individual variations is still limited. Increasing 
efforts are being made to uncover these and includes focus on pharmacogenomics and drug 
transporter proteins.  
 
 
 
Keywords: warfarin, vitamin K antagonists, non-vitamin K antagonists oral anticoagulants, 
dabigatran, rivaroxaban, apixaban, edoxaban, pharmacokinetics and pharmacodynamics, 
atrial fibrillation
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  ARTICLE HIGHLIGHTS BOX 
• Understanding of physiological processes such as the coagulation cascade is 
important to discern how oral anticoagulant (OAC) agents bring about their 
effects 
• Vitamin K antagonists (VKAs) affect multiple components (vitamin K dependent 
clothing factors II, VII, IX, X and proteins C and S) involved in the coagulation 
process whereas the non-vitamin K antagonists (NOACs) are more selective in 
their targets. 
• The pharmacokinetic (PK) and pharmacodynamic (PD) profiles of the OACs vary 
from each other, even when the drugs are structurally similar. They play a key 
role in determining the safety of the drug. 
• Mechanisms of drug interactions include those which affect drug absorption, its 
distribution and the induction or inhibition of enzymes involved in the 
metabolism and elimination of the drug. 
• A good comprehension of the mechanisms of drug interactions is necessary for 
the safe prescription of OACs.  
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1. Introduction 
The discovery of oral anticoagulant (OAC) agents in the form of vitamin K antagonists (VKAs) 
was a boon to mankind and for over 60 years they occupied the limelight as the exclusive 
choice in the long-term the prevention and treatment of stroke associated with atrial 
fibrillation (AF) and other thromboembolic disorders. However, their slow onset of action, 
narrow therapeutic range, titrated dosing, requirement for monitoring, large inter-individual 
variability and multifarious interactions with other drugs and food are amongst the 
limitations which have been a source of numerous clinical plights, giving rise to the 
development of direct or non-vitamin K antagonists (DOACS/ NOACs)[1,2]. Although they 
have similar effects in terms of their clinical effect (i.e. anticoagulant activity), the 
pharmacological profile of NOACs varies to that of warfarin, accounting for their superiority 
in multiple domains.  
 
Hence, a good understanding of the physiological processes as well as the pharmacokinetics 
(PK) [what the body does to the drug] and pharmacodynamics (PD) [what the drug does to 
the body]) of the drugs is necessary to appreciate the differences, so that this knowledge 
can be utilised in the decision-making processes regarding the choice of OAC[3,4]. Hence, 
this review article aims to provide a detailed review of these characteristics of the 
commonly used VKAs (warfarin (Coumadin®), phenprocoumon (Marcoumar®) and 
acenocoumarol (Sinthrome®)) as well as NOACs (dabigatran (Pradaxa®), rivaroxaban 
(Xarelto®), apixaban (Eliquis®) and edoxaban (Lixiana®) . A recent article in this journal by 
Ingrasciotta and colleagues[5] also discusses the pharmacokinetics of NOACs and its 
implications on routine clinical care.  
 
A literature search was conducted on Pubmed using the keywords ‘warfarin’, 
‘phenprocoumon’, ‘acenocoumarol’, ‘vitamin K antagonists’, ‘non-vitamin K antagonists oral 
anticoagulants’, ‘direct oral anticoagulants’, ‘dabigatran’, ‘rivaroxaban’, ‘apixaban’, 
‘edoxaban’, ‘pharmacokinetics’ and ‘pharmacodynamics’ to identify relevant papers.  
 
 
 
1.1 The clotting cascade 
The coagulation cascade comprises of proteolytic enzymes and cofactors, each which 
catalyse the activation of the next, giving rise to an amplification sequence of events which 
ultimately result in the formation of a clot or thrombus.  It may be triggered by two major 
pathways; the intrinsic (contact) and extrinsic (tissue factor) pathways (Figure 1).  Both 
these pathways eventually lead to the formation of prothrombin activator (also known as 
activated factor X) which plays an integral role in the coagulation process[6].  
 
The extrinsic pathway is initiated with trauma to tissue or vascular injury resulting in the 
release of tissue factor (TF), also known as Factor III. TF catalyses the activation of factor VII 
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to VIIa and the tissue factor-VIIa complex then results in the activation of factor X (FX). 
Activated factor X (FXa) along with its co-factor activated factor V (FVa), then result in the 
generation of thrombin (FII) from its precursor prothrombin. Thrombin leads to the 
activation of soluble fibrinogen into insoluble fibrin (FI) monomers which in the presence of 
factor XIII, form fibrin polymers, resulting in the formation of a clot[6]. 
 
The extrinsic pathway initially results in the production of small amounts of thrombin. This 
thrombin activates platelets as well as factors V, VII, VIII, XI and XIII, to further amplify the 
process and lead to formation of more fibrin strands.  
 
The intrinsic pathway is usually triggered where there is trauma to the blood cells or 
exposure of the plasma to artificial surfaces. While it is less significant to haemostasis under 
normal physiological conditions, it is implicated in thrombotic diseases[7]. The intrinsic 
pathway is initiated with the activation of factor XII to FXIIa which catalyses the formation of 
activated factor XI (FXIa). FXIa then acts on factor IX to activate it, so that activated factor IX 
(FIXa) and its activated co-factor FVIIIa can together result in the formation of FXa. Both the 
extrinsic and intrinsic pathways therefore converge at the point where there is activation of 
FX[6] (Figure 1).  
 
FXa plays a crucial role in the coagulation processes arising from both pathways, by 
propagating the fundamental step which is the conversion of prothrombin to thrombin. 
Further, it is key in the amplification process as one molecule of FXa catalyses the formation 
of approximately 1000 molecules of thrombin[8], making it an attractive target to hinder the 
coagulation process[9]. Currently, the majority of NOACs (rivaroxaban, apixaban and 
edoxaban) specifically target FX, while the remaining NOAC dabigatran inhibits thrombin. All 
of these are target specific, unlike VKAs which affect multiple components in the cascade, as 
demonstrated in figure 1. 
 
This is amongst the reasons why NOACs have a favourable safety profile (Table 3), 
particularly in their r duction of the risk of intracerebral haemorrhage (ICH) when compared 
to VKAs[10]. In particular, VKAs affect factor VII which plays a crucial part in brain 
haemostasis[11]. 
 
Fibrinolysis begins once the structural integrity of the vessels starts to get restored. 
Endothelial cells secrete tissue plasminogen activator which activates the protease plasmin 
to degrade fibrin.  Thrombin also gives rise to plasmin from plasminogen, which acts directly 
on the mesh networks of fibrin to break them apart[12]. Moreover, it stimulates production 
of anti-thrombin through a negative feedback loop, which in turn decreases the amount of 
thrombin generated from prothrombin as well as the activated FXa. Another natural anti-
thrombotic mechanism of the body is the protein C/S system which is also influenced by 
VKAs due to their vitamin K dependence[13]. 
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2. Vitamin K antagonists 
The discovery of VKAs was inadvertent, starting with the perplexing deaths of cattle which, 
on post-mortem were found to have extensive bleeding and bruising. The source of this was 
identified as sweet clover and the condition was subsequently dubbed ‘haemorrhagic sweet 
clover disease’. It was soon discovered that this was associated with a deficiency of 
prothrombin and the role of vitamin K in preventing bleeding was established.  
 
Although first used commercially as a rodent poison, warfarin was approved for medical use 
in 1954 and has been in the market since[14]. Phenprocoumon and acenocoumarol, 
followed shortly afterwards and are used in many countries. Other vitamin K antagonists 
include dicoumarol, fluindione, phenindione etc which are not as extensively used[15,16] 
Table 1 summarises the pharmacokinetic properties of the commonly used warfarin, 
phenprocoumon and acenocoumarol.  
 
 
2.1 Mechanism of action  
The coagulation factors II, VII, IX and X require γ-carboxylation for their biological activity, 
with vitamin K acting as a co-factor for this process; hence why they are regarded as the 
vitamin K dependent clotting factors. Under normal circumstances, γ-carboxylation induces 
a conformational change in these coagulation proteins that promotes their binding to co-
factors on phospholipid surfaces.  
 
The carboxylation reaction also involves the simultaneous oxidation of vitamin KH2 (reduced 
form of vitamin K) to vitamin K epoxide (Figure 2). As vitamin K is recycled, the vitamin K 
epoxide is reduced back to vitamin KH2 via a 2-step process. It is first converted to vitamin 
K1, the natural food form of vitamin K, and then vitamin KH2.. Both of these are reductase 
processes but only the first is sensitive to VKAs. VKAs non-competitively inhibit the vitamin K 
epoxide reductase complex subunit 1 (VKORC1), preventing the enzyme from catalysing the 
first reaction. Although VKAs interfere with the coagulation process by limiting the recycling 
of vitamin K, this can be counteracted by replacement of vitamin K1 through oral 
supplementation with food or therapeutic administration due to the second step being 
unaffected by these drugs. Vitamin K1 can accumulate in the liver and can result in warfarin 
resistance for up to a week, if present within the system in large amounts[17,18].   
 
In addition to this, VKAs also inhibit the carboxylation process of the proteins C and S that 
are part of the body’s natural anticoagulant system, and may potentially induce a pro-
coagulant effect. However, their anticoagulant effect is dominant in most 
circumstances[13,17]. 
 
The protective action of VKAs arises from their effect on prothrombin which is prerequisite 
to thrombus formation. Although an anticoagulant effect is initiated within 2 days, the full 
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antithrombotic effect requires a longer period of 6 days due to the long half-life of factor II 
(prothrombin) which is about 60 to 72 hours[19]. 
 
The concentration-effect of VKAs is variable. In a study by Penner and colleagues, treatment 
with warfarin for 14 days resulted in a reduction in FVII and X levels compared to the control 
by 30% and 20% respectively. Warfarin concentrations at this point were 1.2mg/L. In 
contrast, Porter et al demonstrated FX activities which were 60% of that of the control after 
warfarin intake for a similar period. Plasma concentrations of warfarin were 2.5mg/L[20].  
 
 
2.2 Measuring VKA effects 
The international normalised ratio (INR) is universally used as a standardised measure of the 
anticoagulant activity of VKAs. It is defined as the ratio of prothrombin time (PT) measured 
in a patient to that of a control, measured as per the World Health Organisation primary 
standard. PT is the time required for coagulation to occur in vitro and is initially reflective of 
the reduction in factor VII which has a short half-life of 6 hours[21]. Thereafter, factors X 
and prothrombin which have longer half-lives contribute to it[22]. 
 
 
2.3 Warfarin 
Warfarin is the most widely used VKA. It is a highly water soluble compound made up of 
roughly equal proportions of both its R and S isomers. All VKAs exist as roughly equimolar 
racemic mixtures of their two, optically active R and S enantiomers, each which have 
different chemical properties. In a study that involved administration of single doses of both 
R and S warfarin to healthy volunteers, O’Reilly and colleagues demonstrated that the area 
under the plasma concentration time curve (AUC) was 1.9 times higher for R-warfarin than 
S-warfarin warfarin, indicating a lower clearance rate for the R-form. Further, they also 
showed that the inhibitory effect of S-warfarin on prothrombin was 1.8 times higher than R-
warfarin, suggesting that the S-form is about two to five-fold more potent than the R-form. 
This is also true for phenprocoumon and acenocumarol[23–26]. 
 
Absorption: Warfarin is rapidly absorbed from the gastro-intestinal (GI) tract following oral 
administration, with the stomach and proximal GI tract being the main sites. Maximal 
plasma concentrations (Cmax) are achieved within 3-9 hours of oral administration[27]. 
Warfarin absorption is dissolution-rate controlled but there are several other factors that 
can influence this. Significant inter-individual variations also exist[27]. Warfarin has an 
essentially complete oral bioavailability[28].  
 
Distribution: Over 99% of warfarin found in the plasma is protein-bound with virtually all of 
it attached to albumin[27]. Consequently, only a small amount of free drug is available to 
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exert its biological effects. The volume of distribution ranges from 8-12% of the total body 
weight and this does not differ significantly between the enantiomers[28]. 
 
Metabolism: The metabolism of warfarin is stereoselective and the two enantiomers 
undergo hepatic transformation via different pathways[29] by the hepatic cytochrome P450 
(CYP450) enzymes. The CYP450 enzymes involved include CYP 2C9, 2C19, 2C8, 2C18, 1A2, 
and 3A4. The more potent S-warfarin is metabolised by CYPC29 while CYP1A2 and CYP3A4 
are predominantly responsible for the metabolism of R-warfarin[30].  These enzymes 
catalyse the hydroxylation reactions which result in the formation of inactive, hydroxylated 
metabolites as well as cis- and trans-dehydro-warfarins. Five different hydroxylated 
metabolites of warfarin have been identified. Furthermore, two diastereomeric alcohols 
with minimal antiacoagulant activity are also formed via reduction processes which occur in 
the endoplasmic reticulum and cytosol[31,32]. Limited data are available on the phase II 
metabolism of warfarin which includes the glucuronidation and sulfation of hydroxylated 
metabolites. This has been mainly observed in rats in which the R-warfarin metabolites had 
undergone either glucuronidation, sulfation or both[33]. In humans however, these 
reactions appear to be insignificant.[32] CYP2C9 is the primary enzyme responsible for the 
metabolism of warfarin and patients with polymorphisms of these enzymes which have a 
reduced function require lower doses of warfarin due to their risk of over-
anticoagulation[30,34,35].  
 
Excretion: The elimination of warfarin is almost exclusively dependent on metabolism, with 
hydroxylation and reduction processes encompassing 80-85% and 15-20% of metabolic 
clearance respectively[29]. As a result, only miniscule amounts of unchanged drug are 
excreted. Approximately 80% of the metabolites are recovered in urine while the other 20% 
is excreted via the faecal route[36]. The half-life of R-warfarin is 45 hours and S-warfarin is 
29 hours, leading to an overall half-life which ranges from 36-42 hours[22]. The effects of 
warfarin can last from 2-5 days[37].  
 
Interactions: A myriad of interactions occur between warfarin and other drugs, as well as 
food, owing to a number of mechanisms (Table 4). These include agents that affect the 
absorption of warfarin (e.g. cholestyramine and sucralfate), its metabolism (e.g. CYP450 
inhibitors or inducers such as rifampicin and phenobarbital) or displacement from the 
protein binding sites (e.g. quinidine) which can increase the amount of free drug available to 
exert anti-coagulant effects[38,39]. In addition, interactions may also depend on which of 
the isomers are affected as their potency and clearance differs from one another[23]. For 
example, phenylbutazone when co-administered with warfarin, results in effects which are 
stereo-selective. Like warfarin it has a high affinity for plasma proteins, leading to warfarin’s 
displacement from its albumin binding sites and increased plasma concentrations of active 
warfarin. As phenylbutazone is a selective inhibitor of CYP2C9, metabolism of the potent S-
enantiomer of warfarin and therefore its clearance, is reduced[29]. Appropriate dose 
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adjustments or complete avoidance of an interacting drug may be necessary to avoid 
adverse reactions.  
 
 
2.4 Phenprocoumon 
Phenprocoumon is another vitamin K antagonist and coumarin derivative which like the 
others. It is more commonly used in European countries such as Germany. In healthy 
volunteers who took 12mg of phenprocoumon, there was an earlier prolongation of PT, 
than there was a reduction in prothrombin.[40] 
 
Absorption: phenprocoumon is rapidly absorbed after oral intake and has an oral 
bioavailability of 100%[32].  
 
Distribution: over 99% of phenprocoumon is protein bound and it has a volume of 
distribution between 0.11-0.14 L/kg[40]. 
 
Metabolism: phenprocoumon undergoes phase I metabolism by CYPC29 enzymes 
predominantly, resulting in the formation of its 4 inactive, hydroxylated metabolites[41]. 
These then undergo phase II metabolism via glucuronidation[41,42]. Other enzymes 
implicated in the metabolic processes include CYP 2C8 and 3A4 classes which have been 
identified using recombinant CYP enzymes within prepared human liver microsomes[43].   
 
Excretion: unlike warfarin and acenocoumarol whose elimination is almost entirely 
dependent on metabolism, only 60% of phenprocoumon is excreted as metabolites. The 
remainder is removed in an unchanged form. The majority (about 65%) is eliminated by the 
kidneys and the other 35% is[41] excreted via the faeces. The terminal half-life of 
phenprocoumon is much longer in comparison to the others. This is thought to be 
secondary to the lower intrinsic clearance of the enzymes involved in the hydroxylation 
reactions as well as the extensive entero-hepatic recycling of the conjugated 
phenprocoumon[32].  
 
Interactions: given the involvement of the CYP C29, 3A44 and 2C8 enzymes in 
phenprocoumon metabolism, any drugs which can affect their function can result in adverse 
reactions, when given together with phenprocoumon. However, phenprocoumon is much 
less susceptible to interactions compared to warfarin and acenocoumarol, owing to the 
different pathways of metabolism and excretion. For example, cimetidine when given 
together with warfarin results in its increased plasma levels and prolongation of PT but 
these parameters were unaffected when administered with phenprocoumon[44,45]. This is 
explained by its effects on the enzymes CYP1A2 and CYP 2C19 which are involved in the 
metabolism of warfarin but play no role in that of phenprocoumon.  
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2.4 Acenocoumarol  
Acenocoumarol also belongs to the family of VKAs and is used considerably in France and 
Italy. The clinical activity of acenocoumarol is mainly dependent on R-acenocoumarol 
despite being the less potent isoform, due to its longer half-life.[46] 
 
Absorption: Acenocoumarol undergoes rapid absorption after oral intake with Cmax being 
achieved within 3hours[47]. In contrast to the other VKAs, the S-enantiomer of this drug 
undergoes first pass metabolism, making its oral bioavailability relatively lower, though still 
high (96%)[15]. 
 
Distribution: Approximately 98% of acenocoumarol is protein-bound within the plasma[47]. 
Its volume of distribution ranges from 0.22-0.52 L/kg[32]. 
 
Metabolism: The metabolism of acenocoumarol takes place in the liver with CYP2CP playing 
the major role. It exclusively hydroxylates S-acenocoumarol and is also the main enzyme 
involved in the hydroxylation of R-acenocoumarol, which undergoes hydroxylation reactions 
by two other enzymes, CYP1A2 and CYP2C19[48]. Acenocoumarol also undergoes reduction 
to form amino and acetamido metabolites as well as alcoholic forms but the enzymes 
accountable for these processes are undiscovered[32,48].  
 
Excretion: Similar to warfarin, nearly all of the absorbed acenocoumarol is eliminated as 
metabolites with <1% present in urine or faeces in its unchanged form. The proportions 
excreted in urine and faeces are 65% and 35% respectively[47]. 
 
Interactions: drugs affecting the CYP enzymes 1A2, 2C19 and particularly 2C9 can attenuate 
or potentiate the anticoagulant activity of acenocoumarol. When co-administered with 
phenylbutazone which selectively inhibits CYP2C9, the clearance of S-acenocoumarol in rats 
was two times lower[49]. Concurrent administration therefore requires careful 
consideration.  
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3. The Non-vitamin K antagonist oral anticoagulants 
In contrast to VKAs, NOACs are specific in their mode of action, have fixed dose regimens 
without the need for routine monitoring, a rapid onset of action, relatively low inter-
individual variability with consistency seen across age, gender and ethnicity and fewer 
interactions with food and drugs, making them a more convenient and attractive choice 
(Table 2)[50]The four large phase III trials which have led to the licensing of dabigatran, 
rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation are the Randomized 
Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial[51], Rivaroxaban Once Daily 
Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of 
Stroke and Embolism Trial in Atrial Fibrillation (ROCKET-AF)[52], Apixaban for Reduction of 
Stroke and Other Thromboembolic Evens in Atrial Fibrillation (ARISTOTLE)[53] and Effective 
Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation–Thrombolysis in 
Myocardial Infarction 48 (ENGAGE AF-TIMI 48) trials respectively[54]. These drugs have also 
received approval for use in the treatment and prevention of venous thromboembolism 
(VTE).Additionally, in light of recent evidence indicating a reduced risk of cardiovascular 
mortality, myocardial infarction (MI) and stroke, low-dose rivaroxaban is approved for use in 
patients with acute coronary syndromes.[55–57] Table 3 summarises the main safety 
outcomes of these drugs in the respective trials.  
 
3.1 Measuring NOAC effects 
Although the inter-and intra-subject variability in the PK of NOACs have been reported as 
low, notable variations in drug blood levels have been observed in phase III trials of NVAF 
patients[58,59]. Further, these levels have been shown to correspond with efficacy and 
safety outcomes. In a pre-specified PK analysis of the RE-LY trial, the risk of ischemic events 
inversely correlated with dabigatran trough levels (p=0.045), while the major bleeding risk 
increased with dabigatran exposure (p<0.0001). Significant variations were observed in 
plasma concentration and renal function was identified as the predominant characteristic 
determining this, with age, weight and female sex also acting contributing factors. The 
median trough levels were 55% higher in subjects who had a bleeding event, compared to 
those who did not[60].  
 
Similarly, a further analysis from the ENGAGE-TIMI-AF trial also demonstrated a dose-
response relationship with higher rates of ischemic and bleeding events occurring in 
patients who had dose reductions, although the efficacy of edoxaban compared to warfarin 
was reportedly preserved. These findings question the lack of need for routine monitoring 
of plasma concentrations, at least for a subset of patients whose clinical characteristics may 
influence concentrations or who may be at an increased risk of developing ischaemic/ 
bleeding complications despite being on the indicated dose. The PK analysis of the RE-LY 
trial well-demonstrated the wide variation in plasma drug concentrations and the wide 
therapeutic range of dabigatran etexilate. Hence, determining an arbitrary cut-off level to 
guide dose changes can be challenging. At the same time, a dose reduction based on a 
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certain clinical characteristic alone, intended to reduce risks of bleeding, may occur at the 
expense of a much higher risk of stroke.  
 
In a study by Testa et al.[61] attempting to determine a relationship between DOAC trough 
levels and thromboembolic events, these complications were observed only in patients who 
had very low trough levels. 40.5% of the 565 patients in the study were treated with lower 
doses, as per recommendations from the guidelines due to presence of renal dysfunction 
and other indications. The mean CHA2DS2-VASc score was notably higher in this group 
compared to the total patient population (5.3 vs. 3.0) but thromboembolic complications 
were not reported in high cardiovascular risk group that had higher anti-coagulant levels. 
The study’s findings also demonstrated a high inter-individual variability in drug trough 
levels at steady state; suggesting older age, multiple co-morbidities and increasing use of 
prescription drugs as possible factors contributing to this and thus the anti-coagulant effect.  
 
The authors highlighted that the fixed dose of DOACs may therefore not be applicable to the 
‘real-word patient’ whose profile may not fit that of a trial subject on whom the dose 
calculation would have been based on. While these are points to consider, the study 
population was small and subject to effects of confounders such as non-compliance. Further 
large scale studies are needed to confirm these findings.[61] Moreover, dose-adjustment 
studies in the future may enable individualisation of DOAC therapy for better outcomes, 
particularly for those patients whose drug levels fall outside the desired range.  
 
Current guidelines do not mandate regular monitoring of NOAC levels due to their wide 
therapeutic range and predictable PK[62]. That said, the measure of anticoagulant effect 
may still be useful in certain situations where treatment decisions can be influenced (e.g. in 
determining whether an urgent procedure can be performed safely) or in the identification 
of treatment adherence or overdose[63]. Although NOACs affect PT, INR and aPTT to 
varying degrees, these changes do not accurately correlate to their anticoagulant 
activity,[64] only providing qualitative evidence for the anticoagulant activity. Even then, the 
effects are inconsistent with the sensitivity of PT particularly poor for apixaban, while aPTT 
which can only be used in the qualitative assessment of dabigatran is also inconsistent in its 
sensitivity[65]. Hence, these coagulation assays cannot be used as accurate 
measures[66,67].  
 
At present, anti-FXa assays are the only widely available specialised coagulation assay that 
allows a quantitative assessment of the FXa inhibiting NOACs (apixaban, rivaroxaban and 
edoxaban). This is reliable as plasma concentrations of NOACs closely correspond to their 
anticoagulant activity[68]. Anti FIIa assays (including ecarin-based anti FIIa assays) and the 
HEMOCLOT assay where the diluted thrombin time (TT= time taken for the formation of a 
stable clot) is measured in a 1:16 dilution of patient plasma compared with normal pooled 
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plasma, and calibrated; can be used as quantitative measures of dabigatran activity. 
Unfortunately, these are not widely available yet[65,66,69].   
 
 
3.2 Dabigatran etexilate  
Dabigatran is a synthetic, non-peptidic small-molecule direct thrombin inhibitor (DTI) which 
affects both clot-bound and free thrombin in a competitive, reversible and concentration-
dependent manner[70]. It inactivates thrombin by binding to its active site and as this is a 
reversible interaction, a small amount of free, active thrombin is still available for control of 
haemostasis[71,72].  
 
Dabigatran etexilate is a prodrug that was created owing to the low oral bioavailability of 
dabigatran (6-7%), due to its high polarity[73]. It is rapidly converted to its active form 
dabigatran, once absorbed. While it may be consumed with or without food, modification of 
the capsule by crushing or chewing it is discouraged as the oral bioavailability of dabigatran 
etexilate increases by 75% once the capsule shell is broken[74].  
 
Absorption: in order to enhance absorption, the chemical composition of dabigatran 
etexilate is less basic and less hydrophilic, compared to its active form[75]. The drug 
formulation constitutes tartaric acid along with the active ingredient, which provides an 
acidic micro-environment that facilitates drug dissolution and absorption in the stomach 
and small intestine, regardless of the individual gastric pH[76].[77] In pharmacokinetic 
analyses of dabigatran etexilate in healthy males, peak plasma concentrations from the time 
of administration of 2 hours was observed, with steady state concentrations achieved within 
72 hours with multiple dosing[73]. 
 
Distribution: Dabigatran has a volume of distribution of approximately 60-70L, indicative of 
moderate tissue distribution[72]. Only about 35% of the drug is bound to human plasma 
proteins[78]. The distribution phase is rapid, with plasma concentrations declining to <30% 
from peak levels, within 4-6 hours[79]. 
 
Metabolism:  Once absorbed, nearly all of the dabigatran etexilate is hydrolysed to its active 
form. This reaction is catalysed by esterases within the enterocytes and continues along its 
transit  to the portal vein and liver.[77,78] Dabigatran does not undergo significant oxidative 
metabolism reactions[78]. Up to 20% of it undergoes glucuronidation in a hepatic phase II 
reaction and these conjugated products have similar properties to and are as 
pharmacologically active as unconjugated dabigatran[78].  
 
Excretion: While the 20% of the dabigatran that undergoes hepatic biotransformation gets 
excreted in bile, the remaining 80% is excreted by the kidneys in an unchanged form[78]. 
Given that dabigatran is predominantly cleared by the kidneys, dose adjustments are 
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required in patients with renal impairment to prevent its accumulation of drug levels within 
the plasma once creatinine clearance (CrCl) is ≤30ml/min[55,80]Regular monitoring of renal 
function is therefore necessary for patients not just on dabigatran but all NOACs as deteriorations 
leading to changes in the estimated glomerular filtration rate (eGFR) have been associated with an 
increase in the risk of major bleeding[81]. The exposure of dabigatran depicted by the area 
under the curve (AUC) is 2.7 and 6 fold higher in those with moderate (CrCl 30-50ml/min) 
and severe (CrCl <30ml/min) renal impairment respectively[82]. 
 
Interactions: The risk of food-drug and drug-drug interactions is low with dabigatran due to 
the lack of involvement of cytochrome p450 and similar oxidoreductase enzymes[72,78]. 
However, drug interactions may occur during the absorption phase as dabigatran etexilate is 
a substrate for permeability glycoprotein (P-gp) transporter present in the entire 
instestine[83]. P-gp is involved in the active secretion of drugs specific to it from the cells, 
back into the intestinal lumen, resulting in reduced absorption and bioavailability[84]. 
Hence, co-administration with P-gp inducers and inhibitors is not recommended. In a 
population pharmacokinetic analysis from the RE-LY trial, proton-pump inhibitors, verapamil 
and amiodarone affected dabigatran bioavailability significantly but only to moderate 
amounts[80]. Dose adjustments are only required with concurrent administration of P-gp 
inhibitors such as dronedarone and ketoconazole, in the presence of moderate renal 
impairment while complete avoidance is recommended with severe renal impairment[85]. 
 
 
3.3 Rivaroxaban 
Rivaroxaban is a selective inhibitor of factor Xa affecting both free and prothrombinase 
complex bound levels[86]. It also affects clot-bound factor Xa, inhibiting further generation 
of thrombin within the clot and thereby, the extension of the thrombus[87]. Rivaroxaban 
also results in prolongation of PT and aPTT, with maximum inhibition of factor Xa activity 
occurring within 3 hours after dosing[87].  
Rivaroxaban is available as a film-coated tablet and can be safely taken crushed or 
suspended in water, if within 4 hours[88]. 
 
Absorption: Rivaroxaban is primarily absorbed in the stomach, in a process which is 
unaffected by medications that alter the gastric pH.[89] Absorption is reduced in the 
proximal part of the small intestine (resulting in a drop in the AUC for plasma concentration 
and Cmax by 29% and 56% respectively), and even further in the distal small bowel and 
ascending colon[90]. It has a bio-availability that is dose dependent. For low doses of 
rivaroxaban (10mg or below), the bio-availability is high (80-100%) regardless of whether it 
is taken with or without food, while this is reduced at higher doses (15mg and 20mg), 
particularly in fasted states due to absorption limited by the dissolution rate. Hence, 
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administration with food is recommended as this increases bioavailability by up to 80% due 
to an increased residence time within the stomach thought to enhance solubility and 
dissolution[75,91].  
Distribution: The majority of rivaroxaban (92-95%) is bound to plasma proteins; 
predominantly albumin. Its volume of distribution is 50L, indicative of tissue distribution 
that is moderate. However, dose adjustments are not required in the extremes of body 
weight. In a phase I study involving administration of rivaroxaban to healthy individuals 
weighing ≤50kg, 70-80kg and >120kg, Cmax was largely unaffected except in those weighing 
≤50kg, where only a marginal increase was observed[92].  
Metabolism: rivaroxaban is predominantly metabolised in the liver, with two-thirds of the 
drug undergoing oxidative degradation and hydrolysis by cytochrome 3A4 (CYP3A4) and 
cytochrome 2J2 (CYP2J2) enzymes as well as CYP independent pathways[55,93].  
Excretion: About half of the drug that undergoes hepatic biotransformation is excreted by 
the kidneys while the other half takes the hepatobiliary route. The third which does not 
undergo metabolic degradation in the liver, is excreted in the urine an unchanged, active 
form[93].  
In a study evaluating the effects of renal impairment on the PK and PD of rivaroxaban, renal 
clearance of rivaroxaban was reduced with the decline in renal function, resulting in 
increased plasma exposure and PD effects. AUC for plasma concentrations were 1.44-fold, 
1.52-fold and 1.64-fold for those with mild (CrCl 50-79ml/min), moderate (30-49ml/min) 
and severe renal impairment (CrCl <30ml/min) respectively, when compared to those with 
CrCl ≥80ml/min[94].   
Similarly, in another study evaluating the effects of hepatic impairment, significant increases 
in plasma concentrations of rivaroxaban were observed in those with moderate hepatic 
impairment (AUC = 2.27-fold compared to healthy subjects) resulting in significant increases 
in PD effects[95]. This has not been studied in patients with severe hepatic impairment. 
Hence, dose adjustm nts are required when CrCl is ≤50ml/min and in patients with hepatic 
impairment associated with coagulopathy. Caution is warranted in its use in those with 
moderate hepatic impairment that is not associated with coagulopathy[55]. 
Interactions: in addition to being a substrate of the CYP3A4 and CYP2J2 enzymes, 
rivaroxaban is also a substrate for the transporters P-gp and BCRP (breast cancer resistant 
gene protein). The latter is found abundantly within the epithelial cells of organs such as the 
liver, gut and kidney and can influence PK processes of the drug[96,97]. However, the 
clinical impact of this transporter is not known at present.  
Concurrent administration of rivaroxaban with potent inhibitors of P-gp and/ or CYP3A4 
such as azole-antimycotics and  HIV protease inhibitors is not recommended while caution is 
advised with use of agents that affect P-gp and/or CYP3A4 to a lesser extent[55,98]. Care is 
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also warranted when used alongside potent CYP3A4 inducers which can decrease 
rivaroxaban exposure[55].  
Antiplatelet agents such as aspirin and NSAIDs such as naproxen do not affect the PK of 
rivaroxaban but have been shown to independently increase the bleeding time when 
concurrently given. 
 
3.4 Apixaban  
Apixaban  propagates its anticoagulant activity by inhibiting factor Xa in a highly selective 
and reversible fashion. Not only does it affect factor Xa which is free, clot-bound and found 
in the prothrombinase complex but its subsequent attenuating effect on thrombin 
generation leads to the indirect inhibition platelet aggregation induced by thrombin[99]. 
Hence, it can prolong prothrombin time (PT), international normalised ratio and  activated 
partial thromboplastin time (aPTT)[86,100]. 
 
Absorption: Apixaban has an oral bioavailability of about 50% regardless of whether taken 
with or without food. It is primarily absorbed in the distal small bowel and ascending colon, 
while some absorption also takes place in the stomach[101]. In healthy individuals, Cmax is 
achieved within 3hrs of oral administration[102].  
 
Distribution: Approximately 87% of apixaban is bound to plasma proteins, namely 
albumin[103]. Unlike the other NOACs, apixaban has a relatively small volume of 
distribution of 21L, meaning distribution is limited within tissues and mainly confined to the 
blood[103]. In a study looking into the effects of extremes of body weight on the PK and PD 
of apixaban, only a modest increase in drug levels was noted with the Cmax increasing by 
27%. Dose adjustments are therefore not required based on body weight alone but may be 
indicated in the presence of other factors such as renal impairment which may have an 
additive effect on Cmax levels[55,104]. 
 
Metabolism: Apixaban is largely unchanged within the plasma but a quarter of the orally 
administered dose undergoes metabolism in the liver and is recovered in the urine and 
faeces as metabolites. It undergoes O-demethylation, hydroxylation and sulfation reactions 
which are principally catalysed by the CYP3A4 enzymes, although there is minor 
involvement of cytochromes CYP1A2, 2C8, 2C9, 2C19 and 2J2[105]. O-demethyl apixaban 
sulfate is the significant metabolite found in the plasma[105].  
 
Excretion: Of the NOACs, apixaban is least dependent on the kidneys for elimination. Renal 
clearance accounts for about a third (12-29%) of the absorbed dose while the remainder is 
removed via the faecal route either through biliary or direct intestinal excretion (55%)[105]. 
In a study looking into the effects of renal impairment, increases in plasma exposure of 
apixaban were observed as the renal function declined. The AUC for apixaban was 16%, 29% 
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and 38% higher in those with mild, moderate and severe renal impairment respectively, 
compared to those with normal renal function (24h CrCl =100ml/min). Cmax, anti-FXa activity 
and INR were unaffected across all levels of renal impairment. Hence, dose adjustments are 
not required based on renal function alone[106].  
 
In the case of hepatic impairment, the AUC for apixaban following a dose of 5mg of 
apixaban increased by 1.03-fold and 1.09-fold in patients with mild (Child-Pugh A) and 
moderate hepatic impairment (Child-Pugh B) respectively, when compared with normal 
subjects. Protein binding and therefore the fraction of free, unbound drug remained similar 
across the three groups. Further, the percentage change from the baseline INR was also 
comparable between them, although the baseline INR values were higher for those with 
hepatic impairment[107]. Apixaban may therefore be used with caution in those with mild 
to moderate hepatic impairment or in those with liver function enzymes (aspartate amino 
transferase and alanine aminotransferase) which are over 2-fold the upper limit of normal 
but is contra-indicated in those with severe liver disease or that which is associated with 
coagulopathy or high risk of bleeding[55].  
 
Interactions: The numbers of drug-drug interactions with apixaban are low due to the low 
concentrations of drug required within the plasma, largely unchanged form and the various 
pathways of clearance[108]. However, like rivaroxaban, as it is a substrate for CYP3A4 as 
well as the P-gp and BRCP transporter proteins, concomitant administration with potent 
systemic inhibitors and inducers of these is not recommended[55]. Co-administration of 
apixaban and ketoconazole, a strong dual inhibitor of CYP3A4 and P-gp, led to an increase in 
the Cmax and AUC of apixaban by 62% and 99% respectively. However, this effect was less 
pronounced (Cmax of 31% and AUC of 40%) when apixaban was given together with 
diltiazem, which is a moderate inhibitor of CYP3A4 and P-gp[109]. In another study looking 
into the effects of rifampicin which is a strong inducer of CYP3A4 and P-gp, Cmax and AUC 
were significantly decreased and the mean apparent clearance of apixaban increased by 2.1-
fold[110]. Although not contra-indicated, plasma concentrations of apixaban can be 
affected to varying d grees even when given together with less potent CYP3A4 and P-gp 
inhibitors/ inducers. Therefore, careful consideration is required before concurrent use of 
these medications[55]. 
 
 
3.5 Edoxaban  
Edoxaban  is the newest of the NOACs to receive approval for use. It is a selective, small 
molecule inhibitor of factor Xa which binds to it in a competitive and dose-dependent 
manner[111]. This in turn inhibits the generation of thrombin, and the subsequent 
processes that follow. Edoxaban affects free FXa, prothrombinase and also inhibits 
thrombin-induced platelet aggregation[112]. Like the other factor Xa inhibitors, edoxaban 
causes modest increases in INR, PT and aPTT[113]. 
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Absorption: Edoxaban is available as a film coated tablet and may be taken with or without 
food[114]. It has an absolute oral bioavailability of 62%[115]. Absorption in the colon is 
limited and predominantly occurs in the proximal small intestine. Cmax is established rapidly 
within 1-2 hours of taking the medication and steady state is achieved after 72 hours[116].  
 
Distribution: Approximately 55% of edoxaban is protein-bound in the plasma, which is 
lesser than the other FXa inhibitors. It is extensively distributed throughout the body with a 
volume of distribution of 107L[117]. 
 
Metabolism: Unchanged edoxaban is most prevalent in the plasma but a small amount is 
present as metabolites. The major metabolic pathway which results in 25% of the total dose 
undergoing hydrolysis, is catalysed by the enzyme carboxyl esterase-1 present in the cytosol 
and liver microsomes. This gives rise to the major metabolite of edoxaban M-4, which is 
active but accounts for less than 10% of the total edoxaban plasma exposure[118].  Minimal 
metabolism also takes place via the phase I processes of oxidation and conjugation, 
mediated by the CYP3A4 enzymes[119]. Edoxaban also undergoes phase 2 metabolism 
through glucuronidation. In total, six phase 1 metabolites and a glucuronide have been 
detected in human plasma. However, in the absence of severe renal impairment and CYP 
inducers, these do not contribute substantially to edoxaban’s anticoagulant activity[118].  
 
Excretion: 50% of edoxaban is excreted via the kidneys in an unchanged form while biliary 
excretion and metabolism make up for the other half[120]. In the study by Bathala and 
colleagues which involved administration of radiolabelled edoxaban to six, healthy male 
subjects, over 97% of the administered dose was recovered on average, with 35.4% 
eliminated in the urine and 65.2% in faeces[118].  
As renal function declines, plasma levels of edoxaban rise but only to a certain extent, as it is 
just one of the elimination pathways for edoxaban. In a pharmacokinetic study, the total 
exposure of edoxaban increased by 32%, 74% and 72% in individuals with mild (CrCl 50-80 
ml/min), moderate (CrCl 30-50ml/min) and severe (CrCl <30ml/min) respectively compared 
to those with a renal function. There was no significant difference between moderate and 
severe renal insufficiency. Metabolic clearance plays a more dominant role in these 
patients[117].  
The effects of hepatic impairment on edoxaban PK and PD have also been studied. 
Administration of 15mg of edoxaban to patients with mild and moderate hepatic 
impairment resulted in plasma exposure AUCs of 95.9% and 95.2% compared to their 
respective controls, indicating a minimal effect. Furthermore, PT was only slightly prolonged 
in these subjects compared to the healthy subjects, while aPTT profiles were similar across 
all groups[121]. Nonetheless, edoxaban is contra-indicated in patients with severe hepatic 
impairment and should be used with caution in those with moderate hepatic impairment 
due to the risk of coagulopathy and bleeding[122]. 
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Interactions: much like the other FXa inhibitors, edoxaban is a substrate for the P-gp 
transporter protein and CYP3A4 enzymes. However, as the CYP3A4 enzymes only play a 
minor role in its clearance, plasma exposures of edoxaban are not significantly different to 
each other when administered with drugs that are dual inhibitors of P-gp and CYP3A4, 
whether the latter is mild, moderate or strong[117]. However, significant increases in total 
exposure are still seen due to inhibition of P-gp and dose reductions are required when 
edoxaban is given together with these drugs [122,123].  When administered with rifampicin, 
edoxaban clearance increased by 33% with a reduction in half-life by 50% while PT and aPTT 
did not change significantly. Concurrent use is therefore not contra-indicated but requires 
careful consideration[124]. 
In addition to this, concomitant administration with naproxen and low dose aspirin did not 
alter the PK of edoxaban but high dose aspirin increased edoxaban exposure by about 30%. 
All three, approximately doubled the bleeding time even though INR, PT and APTT were 
unaffected[125]. 
 
 
4. Conclusion 
The pharmacokinetic profiles of the OACs vary from each other to different degrees and 
partly explain the differences in their characteristics and mode of action. The clinical effect 
of the drug is determined not just by one factor, but by a combination of them including 
PK/PD profiles, patient demographics such as age and gender, genetics and environmental 
aspects. Indeed, mechanisms which influence the metabolism and elimination pathways can 
solitarily compromise drug safety.  
Ultimately, it is not a question of which drug has the more superior pharmacological profile, 
but a matter of which pharmacological profile is most suited to the patient’s profile.  
 
 
5. Expert Opinion 
Although OAC agents belonging to the same class of drugs are similar in structure and 
function, there are major differences in their pharmacological profiles. In particular, it is the 
distinctions in the metabolic and elimination pathways are responsible for the 
heterogeneity in drug-drug and food-drug interactions which either attenuate or potentiate 
the anticoagulant activity.  
 
Hence, insight to the pharmacokinetics and pharmacodynamics is necessary in order to 
achieve the maximal therapeutic benefit and minimise the possibility of adverse reactions. It 
is also of relevance so that an informed choice can be made between the drugs. That said, 
other processes such as factors influencing absorption of the drugs and pharmacodynamic 
interactions also play a role.  Warfarin and VKAs, though expected to be replaced by NOACS, 
are likely to remain in play due to the breadth of experience with their use and because they 
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are the only OACs currently licensed for use in special populations such as those with 
mechanical prosthetic valves and rheumatic atrial fibrillation[15]. As such, the focus should 
not be shifted away from VKAs just yet and further research is needed to better understand 
its behaviour.  
 
The use of warfarin remains problematic due to the diversity of its interactions and the 
multiple patient factors such as age, gender, diet and smoking status which influence its 
response. The inter-individual variations in the dose requirements for warfarin can be up to 
10-fold[126]. Genetic polymorphisms of some of the key enzymes such as VKORC and 
CYPC29 have been attributed to this, where the CYPC29*2 and CYPC29*3  alleles are 
associated with decreased enzyme activity and subsequent increased warfarin levels 
requiring a reduced dose, while single nucleotide polymorphisms in VKORC1 are associated 
with warfarin doses across the normal range[127]. It is estimated that only 60% of these 
differences are accounted for, meaning that factors which are yet to be discovered are 
silently at play[126]. In this regard, drug transporter science aiming to identify and 
characterise different transporter proteins as well as their interplay with the 
pharmacokinetics and subsequent clinical response is an emerging field[128]. Another is 
pharmacogenomics, with the increasing recognition that it is not just the pharmacokinetics 
and pharmacodynamics profile which influences the drug effect.  
 
Since its acknowledgement, pharmacogenomics ha advanced such that guidelines which 
incorporate pharmacogenetics algorithms considering VKORC1 and CYPC29 genotypes now 
exist, in addition to the clinical factors, for warfarin dose prediction[129].  A step ahead of 
this is the implementation of pharmacogenomic diagnostics which involves screening for 
genotype variants prior to initiating anti-coagulation therapy. In a randomised controlled 
trial involving patients with AF and VTE by Pirmohamed and colleagues[130], warfarin was 
prescribed after genotyping, based on pharmaco-genetic algorithms in the treatment group, 
and standard dosing was utilised for the control group.  Results indicated that that the time 
in therapeutic range (TTR) was significantly better in the genotype-guided group, compared 
to the control group. Results from another study by Kimmel and colleagues[131] however, 
showed no significant differences in the TTR between the genotype-guided and control 
groups.  
 
The widespread uptake of pharmacogenomics diagnostics is yet to take place. Routine use 
may be implicated by factors such as cost and pharmaco-economic evaluations may be 
necessary prior to this. However, for a small sub-group of patients who are difficult to 
manage, or at risk of bleeding with labile INRs whose only choice of treatment is VKAs, 
genotyping may be of utmost value to help guide anti-coagulation treatment.  
 
Less emphasis has been made on NOACs in this section, not due to a lesser importance but 
because their PK/PD profiles confer a lesser degree of interactions. Indeed, they too have 
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some important interactions and certain variations in their PK/PD processes are likely to be 
due to genetic polymorphisms, some which are known about (e.g. CYPC29) and some which 
are yet to be discovered. The exact pathophysiology of reported adverse effects such as GI 
haemorrhage also requires further study, while breakthroughs are being made in certain 
avenues such as the development of potential antidotes.[132–134]  
 
Lastly, a key area of NOAC-based research should focus on patients with chronic and end stage 
kidney disease; a prevalent and complex population. The complication rates in terms of major 
bleeding and ICH as well as the challenges in maintaining INR within the desired range with VKAs in 
this group of patients have resulted in a ‘now more than ever’ need for alternative drug agents such 
as DOACs. Unfortunately, all DOAC RCTs excluded patients with CrCl <25-30 ml/min precluding their 
use in these patients.[51–54]Despite this, DOAC usage has been extended beyond the RCT criteria in 
certain countries on the basis of limited pharmacokinetic data. This includes the lower dose of 
dabigatran in patients with renal impairment (CrCl 15-30ml/min) and the use of apixaban in renal 
patients requiring dialysis in the United States, following approval from the Food and Drug 
Administration.[135,136] 
 
The discrepancies in the international guidelines concerning renal dysfunction reflect our 
incomplete knowledge of the pharmacology of NOACs in this group of patients and 
therefore warrant caution, especially as data on the long-term effects is scarce. While data 
from post-approval studies have been informative and  RCT comparing apixaban to 
phenprocoumon in patients undergoing chronic haemodialysis is underway, further studies 
are needed to shed light on the matter [137–139].  
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Vit KH2 = Vitamin KH2, Vit KO = Vitamin K epoxide, Vit K1= Vitamin K1, VKOR = Vitamin K epoxide reductase, VKR = Vitamin K reductase 
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Table 1 
Parameter  Warfarin[23,24,33–37,25–32]  Phenprocoumon[32,40–44] Acenocoumarol[15,46–50] 
Enantiomers R-warfarin S-warfarin 
R-Phenprocoumon 
S-Phenprocoumon 
R-Acenocoumarol 
S-Acenocoumarol 
Maintenance dose (mg/day) 2-15 0.75-9 2-10 
Route of administration Oral Oral  Oral 
Target Vitamin K epoxide reductase Vitamin K epoxide reductase Vitamin K epoxide reductase 
Mechanism of action 
Inhibits vitamin K recycling affecting 
vitamin K dependent clotting factors 
(II, VII, IX and X) 
Inhibits vitamin K recycling affecting 
vitamin K dependent clotting factors 
(II, VII, IX and X) 
Inhibits vitamin K recycling 
affecting vitamin K dependent 
clotting factors (II, VII, IX and X) 
Reversibility Yes Yes Yes 
Pro-drug No No No 
Significant food effect on 
absorption 
No No No 
Bioavailability  100% 100% 96% 
Plasma concentration 
(µmol/L) 
1.5-8 1.5-15 0.03-0.3 
Protein binding  >99% >99% >98% 
Volume of distribution (L/kg) 0.08-0.12  0.11-0.14  0.22-0.52 
Plasma clearance (L/h) S-Warfarin – 0.10-1.0 R- Warfarin – 0.07-0.35 
S-Phenprocoumon – 0.045 – 0.055 
R- Phenprocoumon – 0.055-0.08 
S-Acenocoumarol – 28.5 
R-Acenocoumarol – 1.9  
Elimination half-life (hours) 
S-Warfarin – 24-33  
R-warfarin – 35-58  
S-Phenprocoumon – 110-130  
R- Phenprocoumon – 110-125  
S-Acenocoumarol – 1.8  
R- Acenocoumarol – 6.6 
Metabolism  Hepatic Hepatic Hepatic 
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Metabolic enzymes involved 
S-Warfarin - CYPC29 (major) 
R-Warfarin - CYP1A2 and CYP3A4 
(major) 
Other: 2C19, 2C8, 2C18 and 1A2 
(minor) 
S-Phenprocoumon – CYP2C8, 
CYP2C9 and CYP3A4 
R-Phenprocoumon – CYPC29 and 
CYP3A4  
S-Acenocoumarol – CYP2C9 
R-Acenocoumarol – CYP2C9, 
CYP1A2 and CYP2C19 
Elimination  
Urine (80%) 
Faeces (20%)  
Urine (65%) 
Faeces (35%) 
Urine (65%) 
Faeces (35%) 
Routine monitoring Yes Yes Yes 
Interactions with food Multiple Multiple Multiple 
Drug-drug interactions Multiple Multiple Multiple 
Adverse effects (non-
bleeding)  
Hypersensitivity reactions (urticaria, 
anaphylaxis), calciphylaxis, tissue 
necrosis, systemic atheroemboli, 
cholesterol microemboli, limb 
ischaemia, gangrene, acute kidney 
injury, gastro-intestinal disorders such 
as nausea, vomiting and abdominal 
discomfort. 
Rare – hep titis, skin and tissue 
necrosis[146] 
Rare – nausea, vomiting and 
alopecia, skin necrosis, liver injury, 
vasculitis 
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Table 2  
Parameter  Dabigatran[55,72,81,82,73–80] 
Rivaroxaban[55,87,96,97,88–
95] 
Apixaban[55,100–110] Edoxaban[111–125] 
Route of administration Oral Oral  Oral Oral 
Target Thrombin Factor Xa Factor Xa Factor Xa 
Mechanism of action 
Inhibition of thrombin activity 
and generation of thrombin 
(TF-induced and endogenous) 
Factor Xa inhibitor (affects, 
free, clot-bound and 
prothrombinase complex 
associated FXa) 
Factor Xa inhibitor (affects, 
free, clot-bound and 
prothrombinase complex 
associated FXa) 
Factor Xa inhibitor (free and 
prothrombinase associated 
FXa) 
Reversible interaction Yes Yes Yes Yes 
Pro-drug Dabigatran etexilate No No No 
Significant food effect No 
Yes (reduced absorption in 
fasted state when dose ≥10mg) 
No No 
Site of absorption Stomach and small intestine Stomach 
Distal small intestine and 
ascending colon 
Upper gastro-intestinal tract 
Bioavailability  6.5% 80-100% 50% 62% 
Peak plasma 
concentration from time 
of administration 
2 hours (1.5-3h in healthy 
volunteers) 
2-4 hours 1.5-3.3 hours 1-2 hours  
Protein binding  35% 92-95% 87% 55% 
Volume of distribution 60-70 L 50 L 21 L 107 L 
Time to steady state 
concentrations 
48-72 hours ≤96 hours 72 hours 72 hours 
Elimination half life 12-17 hours 
5-9 hours (healthy) 
9-13 hours (elderly) 
8-15 hours 10-14 hours 
Hepatic metabolism  20% (conjugation only) 67% 25% NR 
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Metabolic enzymes 
involved 
 None 
CYP3A4 and CYP 2J2 (major) 
CYP-independent mechanisms 
CYP3A4 (major) 
CYP1A2, 2C8, 2C9, 2C19 and 
2J2 (minor) 
carboxyl esterase-1 (major) 
CYP 3A4 (minor) 
Excretion (as a % of total 
dose) 
Renal (80%)- unchanged form 
Biliary (20%) 
Renal (67%) – 33% in 
unchanged form 
Hepatobiliary (33%)  
 
Renal (27-30%) 
Hepatobiliary (70%) – direct 
intestinal (major) and biliary 
(minor) 
 
Renal (50%) – unchanged 
form 
Hepatobiliary (50%) 
Routine monitoring No No No No 
Interactions with food No No  No No 
Drug-drug interactions 
Few 
P-gp inducers (e.g. rifampicin) 
P-gp inhibitors in the presence 
of moderate-severe rena 
impairment 
Combined P-gp and strong 
inhibitors of CYP3A4 (e.g. 
ketoconazole, ritonavir) 
Combined P-gp and strong 
inducers of CYP3A4 (e.g. 
rifampicin) 
Combined P-gp and strong 
inhibitors of CYP3A4 (e.g. 
ketoconazole, ritonavir) 
Combined P-gp and strong 
inducers of CYP3A4 (e.g. 
rifampicin) 
Combined P-gp and strong 
inhibitors of CYP3A4 (e.g. 
ketoconazole, ritonavir) 
High dose aspirin  
Digoxin  
Dose adjustment with 
hepatic impairment 
Avoid  if risk of coagulopathy 
No but caution with use if 
moderate impairment 
Avoid  if risk of coagulopathy 
No but caution with use if 
moderate impairment 
Avoid  if risk of coagulopathy 
No but caution with use if 
moderate impairment 
Avoid  if risk of coagulopathy 
Dose adjustment with 
renal impairment 
Yes Yes 
Yes (if present with weight 
≤50kg and/or age ≥80 years) 
Yes 
Adverse effects (non-
bleeding)  
Gastritis like symptoms (15%), 
Dyspepsia  
Rash (≥1%) Skin rash (<1%) 
Rash, abnormal liver function 
tests (≥1%) 
Reversal Agent Idarucizumab Andexanet Alfa Andexanet Alfa Andexanet Alfa 
 
NR = Not reported 
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Table 3 
Trial RE-LY[51] ROCKET AF[52] ARISTOTLE [53] ENGAGE AF-TIMI 48[54] 
Comparators Dabigatran vs. warfarin 
Rivaroxaban vs. 
warfarin 
Apixaban vs. warfarin Edoxaban vs. warfarin 
Time in the 
therapeutic 
range for 
warfarin 
64% 55% 62.20% 68.40% 
Subgroup 
Event rate 
,%/year  (HR, 
95%CI, P value)* 
Dabigatran 150mg 
 
Dabigatran 110mg 
 
Rivaroxaban 20mg 
 
Apixaban 5mg 
 
Edoxaban 60mg 
 
Edoxaban 30mg 
 
Major bleeding 3.11 (0.93; 0.81-
1.07) 
2.71 ( 0.80; 0.69-0.93) 3.60 (1.04, 0.90-1.20; 
P=0.58) 
2.13 (0.69; 0.60-0.80)  2.75 (0.80; 0.71-
0.91) 
1.61 (0.47; 0.41-
0.55) 
Intracranial 
haemorrhage  
 0.30 (0.40; 0.27-
0.60)  
0.23 ( 0.31; 0.20 – 
0.47) 
0.50 (0.67; 0.47-0.93) 0.33 (0.42;  0.30-0.58) 0.39 (0.47; 0.34-
0.63) 
0.26 (0.30; 0.21-
0.43) 
Gastrointestinal 
haemorrhage 
 1.51 (1.50;1.19 – 
1.89) 
 1.12 (1.10; 0.86-1.41)  3.2 (1.42; 1.22-1.66)** 0.76 (0.89; 0.70-1.15) 1.51 (1.23; 1.02-
1.50) 
0.82 (0.67; 0.53-
0.83) 
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All-cause death 3.64 (0.88; 0.77 – 
1.00) 
3.75 (0.91; 0.80 – 
1.03)  
1.9 (0.85; 0.70 – 1.02)  3.94 (0.89; 0.80 – 
0.998) 
3.99 (0.92; 0.83-
1.01)  
3.80 (0.87; 0.79-
0.96) 
 
*The HRs for safety outcomes presented for RE-LY and ARISTOTLE trials are following intention-to-treat analyses, while HRs for ROCKET-AF and ENGAGE-
TIMI-AF trials are following per-protocol per-treatment and modified intention-to-treat analyses respectively.  
**Major or NMCR GI bleeds 
Table 4 
Drugs 
Example Mechanism of interaction 
Antiviral drugs  
Efavirenz Moderate inhibition of CYP2C19 and of CYP3A4 
Nevirapine Strong inhibition of CYP3A4 
Ritonavir Strong inhibition of CYP3A4, inhibition of P-gp  
Saquinavir Inhibition of CYP3A4 
Antifungal drugs 
Itraconazole, Ketoconazole Strong inhibition of CYP3A4 and P-gp 
Voriconazole Strong inhibiton of CYP3A4, CYP1A2, CYP2C9, P-gp 
Fluconazole  Moderate inhibition of CYP3A4, CYP1A2, CYP2C9 
Miconazole gel, Miconazole vaginal suppositories Inhibition of CYP1A2, CYP2C9 
Antibiotics  
Amoxicillin, clavulanic acid Reduction of intrinsic vitamin K synthesis 
Ciprofloxacin Strong inhibition of CYP1A2 
Levofloxacin Inhibition of CYP1A2 
Macrolides E.g. Azithromycin, Clarithromycin, Erithromycin Moderate inhibition of CYP3A4 and P-gp 
Metronidazole Inhibition of CYP1A2 and CYP2C9 
Nafcillin Strong inhibition of CYP3A4 
Nalidixic acid  Inhibition of CYP1A2 
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Norfloxacin Inhibition of CYP3A4 
Isoniazid Inhibition of CYP2C9 
Chloramphenicol Inhibition of CYP450 
Rifampicin Induction of CYP3A4, CYP2C9 and p-gp 
Tetracyclines Inhibition of CYP3A4 
Trimethoprim Inhibition of CYP3A4 
Anti-arrhythmic drugs 
Amiodarone Moderate inhibition of CYP3A4, CYP1A2, CYP2C9 
Dronedarone Moderate inhibition of CYP3A4, inhibitor of P-gp 
Disopyramide Inhibition of CYP3A4 
Propranolol Inhibition of CYP1A2 
Propafenone Inhibition of CYP3A4 
Quinidine Inhibition of CYP3A4 
Other cardiac drugs 
Diltiazem Inhibition of CYP3A4 
Statins (E.g. atorvastatin,lovastatin, rosuvastatin, 
simvastatin) 
Inhibition of CYP3A4 
Telmisartan Inhibition of CYP3A4 
Verapamil Weak inhibition of CYP3A4; inhibition of P-gp 
Anti-epileptic drugs 
Barbiturates (e.g. phenobarbital) Induction of CYP3A44, CYP2J and P-gp 
Carbamazepine Induction of CYP3A44, CYP2J and P-gp 
Phenytoin  Induction of CYP3A44, CYP2J and P-gp 
Other drugs  
Fibrates (E.g. clofibrate, fenofibrate) Inhibition of CYP3A4 
Glucagon Inhibition of CYP3A4 
Proton pump inhibitors (e.g.) Inhibition of CYP2C9 and increased warfarin absorption 
Food 
Examples Mechanism of interaction 
Bishop’s weed, Carum Ajowan, Citrus aurantium (orange), 
Uncaria (Cat’s claw), Dehydroepiandrosterone, Echinacea, 
Goldenseal, Hydrastis Canadensis, Liquorice, Lime, Valerian, 
Inhibition of CYP3A4 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
Wild cherry  
Chamomile Inhibition of CYP1A2, CYP2C9, CYP3A4 
Cranberry, Milk thistle Inhibition of CYP3A4 and CYP2C9 
Devil’s claw, Garlic, Ginsenoside Rd (found in Ginseng) Inhibition of CYP2C9, CYP2C19, CYP3A4 
Eucalyptus, Feverfew, Fo-Ti, Peppermint, Red clover Inhibition of CYP1A2, CYP2C9, CYP2C19, CYP3A4 
Gingko, Lycium (Chinese Wolfberry)  Inhibition of CYP2C9 
Grapefruit juice, Silybum marianum, Resveratrol Inhibition of CYP1A2 and CYP3A4 
Mango Inhibition of CYPC219 
Diindolylmethane, Grapes (Vitis Vinifera), Indole-3-carbinol Induction of CYP1A2 
Ginsenoside Re and Rf (found in Ginseng) Induction of CYP3A4 and CYP2C9 
Guggul Induction of CYP3A4 
Limonene Induction of CYP2C9 
St. John’s Wort Induction of CYP1A2, CYP2C9, CYP3A4 and P-gp 
 
 
 
 
 
 
 
 
 
 
 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
 
 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
References 
1.  Weitz JI, Linkins L-A. Beyond heparin and warfarin: the new generation of 
anticoagulants. Expert Opin Investig Drugs. 2007 Mar 16;16(3):271–82.  
2.  Lip GYH, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial 
fibrillation: Past, present and future. Thromb Haemost. 2017 Nov 8;117(07):1230–9.  
3.  Waller DG, Sampson AP, Waller DG, Sampson AP. Pharmacokinetics. Med Pharmacol 
Ther. 2018 Jan 1;33–62.  
4.  Hallworth M. Therapeutic drug monitoring. Clin Biochem Metab Clin Asp. 2014 Jan 
1;767–86.  
5.  Ingrasciotta Y, Crisafulli S, Pizzimenti V, Marcianò I, Mancuso A, Andò G, et al. 
Pharmacokinetics of new oral anticoagulants: implications for use in routine care. 
Expert Opin Drug Metab Toxicol. 2018 Oct 3;14(10):1057–69.  
6.  Smith SA, Travers RJ, Morrissey JH. How it all starts: Initiation of the clotting cascade. 
Crit Rev Biochem Mol Biol. 2015;50(4):326–36.  
7.  Marder VJ. Hemostasis and thrombosis : basic principles and clinical practice. 
[Internet]. Wolters Kluwer/Lippincott Williams & Wilkins Health; 2012. 1566 p.  
8.  Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 
2003 Jul;1(7):1504–14.  
9.  Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Thromb Haemost. 2007 
Jul 9;5:60–4.  
10.  Wolfe Z, Khan SU, Nasir F, Raghu Subramanian C, Lash B. A systematic review and 
Bayesian network meta-analysis of risk of intracranial hemorrhage with direct oral 
anticoagulants. J Thromb Haemost. 2018 Jul 1;16(7):1296–306.  
11.  Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg. 
2009 May;108(5):1447–52.  
12.  Lijnen HR. Elements of the fibrinolytic system. Ann N Y Acad Sci. 2001;936:226–36.  
13.  Esmon CT, Vigano-D’Angelo S, D’Angelo A, Comp PC. Anticoagulation proteins C and 
S. Adv Exp Med Biol. 1987;214:47–54.  
14.  Wardrop D, Keeling D. The story of the discovery of heparin and warfarin.  
15.  Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, et al. Vitamin 
K antagonists in heart disease: Current status and perspectives (Section III). Thromb 
Haemost. 2013 Nov 30;110(12):1087–107.  
16.  Potpara T. Comparing Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) to 
Different Coumadins: The Win-Win Scenarios. Thromb Haemost. 2018 May 
4;118(05):803–5.  
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
17.  de Boer-van den Berg MA, Thijssen HH, Vermeer C. The in vivo effects of 
acenocoumarol, phenprocoumon and warfarin on vitamin K epoxide reductase and 
vitamin K-dependent carboxylase in various tissues of the rat. Biochim Biophys Acta. 
1986 Oct 29;884(1):150–7.  
18.  Hirsh J, Dalen JE, Deykin D, Poller L, Bussey H. Oral Anticoagulants. Chest. 1995 
Oct;108(4):231S–246S.  
19.  Flier JS, Underhill LH, Wessler S, Gitel SN. Warfarin: From bedside to bench. N Engl J 
Med. 1984 Sep 6;311(10):645–52.  
20.  Holford NHG. Clinical Pharmacokinetics and Pharmacodynamics of Warfarin. Clin 
Pharmacokinet. 1986;11(6):483–504.  
21.  Kim S, Gaweda AE, Wu D, Li L, Rai SN, Brier ME. Simplified Warfarin Dose-response 
Pharmacodynamic Models. Biomed Eng  Appl basis, Commun. 2015 Feb;27(1).  
22.  Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and 
Management of the Vitamin K Antagonists. Chest. 2008 Jun;133(6):160S–198S.  
23.  Breckenridge A, L’E Orme M. The plasma half lives and the pharmacological effect of 
the enantiomers of warfarin in rats. Life Sci. 1972 Apr 8;11(7):337–45.  
24.  Jähnchen E, Meinertz T, Gilfrich HJ, Groth U, Martini A. The enantiomers of 
phenprocoumon: pharmacodynamic and pharmacokinetic studies. Clin Pharmacol 
Ther. 1976 Sep;20(3):342–9.  
25.  Meinertz T, Kasper W, Kahl C, Jähnchen E. Anticoagulant activity of the enantiomers 
of acenocoumarol. Br J Clin Pharmacol. 1978 Feb;5(2):187–8.  
26.  O’Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol 
Ther. 1974 Aug;16(2):348–54.  
27.  Kelly JG, OʼMalley K. Clinical Pharmacokine cs of Oral An coagulants. Clin 
Pharmacokinet. 1979;4(1):1–15.  
28.  Hewick DS, McEwen J. Plasma half-lives, plasma metabolites and anticoagulant 
efficacies of the enantiomers of warfarin in man. J Pharm Pharmacol. 1973 
Jun;25(6):458–65.  
29.  Lewis RJ, Trager WF, Chan KK, Breckenridge A, Orme M, Roland M, et al. Warfarin. 
Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J 
Clin Invest. 1974 Jun 1;53(6):1607–17.  
30.  Kaminsky LS, Zhang Z-Y. Human P450 metabolism of warfarin. Pharmacol Ther. 1997 
Jan 1;73(1):67–74.  
31.  Trager WF, Lewis RJ, Garland WA. Mass spectral analysis in the identification of 
human metabolites of warfarin. J Med Chem. 1970 Nov;13(6):1196–204.  
32.  Ufer M. Comparative Pharmacokinetics of Vitamin K Antagonists. Clin Pharmacokinet. 
2005;44(12):1227–46.  
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
33.  Jansing RL, Chao ES, Kaminsky LS. Phase II metabolism of warfarin in primary culture 
of adult rat hepatocytes. Mol Pharmacol. 1992 Jan;41(1):209–15.  
34.  Higashi MK, Veenstra DL, Kondo LM, Wittkowsky AK, Srinouanprachanh SL, Farin FM, 
et al. Association between CYP2C9 genetic variants and anticoagulation-related 
outcomes during warfarin therapy. JAMA. 2002 Apr 3;287(13):1690–8.  
35.  Lane S, Al-Zubiedi S, Hatch E, Matthews I, Jorgensen AL, Deloukas P, et al. The 
population pharmacokinetics of R- and S-warfarin: effect of genetic and clinical 
factors. Br J Clin Pharmacol. 2012 Jan;73(1):66–76.  
36.  Toon S, Low LK, Gibaldi M, Trager WF, O’Reilly RA, Motley CH, et al. The warfarin-
sulfinpyrazone interaction: stereochemical considerations. Clin Pharmacol Ther. 1986 
Jan;39(1):15–24.  
37.  Baker RI, Coughlin PB, Gallus AS, Harper PL, Salem HH, Wood EM, et al. Warfarin 
reversal: consensus guidelines, on behalf of the Australasian Society of Thrombosis 
and Haemostasis. Med J Aust. 2004 Nov 1;181(9):492–7.  
38.  Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interactions of warfarin with drugs and 
food. Ann Intern Med. 1994 Nov 1;121(9):676–83.  
39.  Martín-Pérez M, Gaist D, de Abajo F, Rodríguez L. Population Impact of Drug 
Interactions with Warfarin: A Real-World Data Approach. Thromb Haemost. 2018 Mar 
12;118(03):461–70.  
40.  Haustein K-O. Pharmacokinetic and Pharmacodynamic Properties of Oral 
Anticoagulants, Especially Phenprocoumon. Semin Thromb Hemost. 1999 Feb 
6;25(01):5–11.  
41.  Toon S, Heimark LD, Trager WF, O’Reilly RA. Metabolic fate of phenprocoumon in 
humans. J Pharm Sci. 1985 Oct;74(10):1037–40.  
42.  He M, Korzekwa KR, Jones JP, Rettie AE, Trager WF. Structural Forms of 
Phenprocoumon and Warfarin That Are Metabolized at the Active Site of CYP2C9. 
Arch Biochem Biophys. 1999 Dec;372(1):16–28.  
43.  Ufer M, Svensson JO, Krausz KW, Gelboin H V., Rane A, Tybring G. Identification of 
cytochromes P 450 2C9 and 3A4 as the major catalysts of phenprocoumon 
hydroxylation in vitro. Eur J Clin Pharmacol. 2004 May 1;60(3):173–82.  
44.  Serlin MJ, Sibeon RG, Mossman S, Breckenridge AM, Williams JR, Atwood JL, et al. 
Cimetidine: interaction with oral anticoagulants in man. Lancet (London, England). 
1979 Aug 18;2(8138):317–9.  
45.  Harenberg J, Staiger C, de Vries JX, Walter E, Weber E, Zimmermann R. Cimetidine 
does not increase the anticoagulant effect of phenprocoumon. Br J Clin Pharmacol. 
1982 Aug;14(2):292–3.  
46.  Thijssen H. Altered pharmacokinetics of R - and S -acenocoumarol in a subject 
heterozygous for CYP2C9*3. Clin Pharmacol Ther. 2001 Sep;70(3):292–8.  
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
47.  Dieterle W, Faigle JW, Montigel C, Sulc M, Theobald W. Biotransformation and 
pharmacokinetics of acenocoumarol (Sintrom) in man. Eur J Clin Pharmacol. 
1977;11(5):367–75.  
48.  Thijssen HH, Flinois JP, Beaune PH. Cytochrome P4502C9 is the principal catalyst of 
racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug 
Metab Dispos. 2000 Nov;28(11):1284–90.  
49.  Thijssen HH, Baars LG, Janssen GM. Phenylbutazone-hydroxycoumarol interactions. 
Effects on steady state disposition, hepatocellular distribution, and biliary excretion 
of (S)-acenocoumarol in rats. Drug Metab Dispos. 16(5):744–8.  
50.  Scaglione F. New Oral Anticoagulants: Comparative Pharmacology with Vitamin K 
Antagonists. Clin Pharmacokinet. 2013 Feb 5;52(2):69–82.  
51.  Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. 
Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2009 Sep 
17;361(12):1139–51.  
52.  Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus 
Warfarin in Nonvalvular Atrial Fibrillation. N Engl J Med. 2011 Sep 8;365(10):883–91.  
53.  Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. 
Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011 Sep 
15;365(11):981–92.  
54.  Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. 
Edoxaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2013 Nov 
28;369(22):2093–104.  
55.  De Caterina R, Husted S, Wallentin L, De Caterina R, Husted S, Wallentin L, et al. New 
Oral Anticoagulants in Atrial Fibrillation and Acute Coronary Syndromes. J Am Coll 
Cardiol. 2012 Apr 17;59(16):1413–25.  
56.  Ahmed Z, Hassan S, Salzman GA. Novel Oral Anticoagulants for Venous 
Thromboembolism with Special Emphasis on Risk of Hemorrhagic Complications and 
Reversal Agents. Curr Drug ther. 2016 Apr;11(1):3–20.  
57.  Mega JL, Braunwald E, Wiviott SD, Bassand J-P, Bhatt DL, Bode C, et al. Rivaroxaban in 
Patients with a Recent Acute Coronary Syndrome. N Engl J Med. 2012 Jan 5;366(1):9–
19.  
58.  Kaserer A, Schedler A, Jetter A, Seifert B, Spahn D, Stein P, et al. Risk Factors for 
Higher-than-Expected Residual Rivaroxaban Plasma Concentrations in Real-Life 
Patients. Thromb Haemost. 2018 May 3;118(05):808–17.  
59.  Sacco M, Lancellotti S, Berruti F, Arcovito A, Bellelli A, Ricciardelli T, et al. Apixaban 
Interacts with Haemoglobin: Effects on Its Plasma Levels. Thromb Haemost. 2018 Oct 
20;118(10):1701–12.  
60.  Reilly PA, Lehr T, Haertter S, Connolly SJ, Yusuf S, Eikelboom JW, et al. The Effect of 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of 
Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients. J Am Coll Cardiol. 
2014 Feb 4;63(4):321–8.  
61.  Testa S, Paoletti O, Legnani C, Dellanoce C, Antonucci E, Cosmi B, et al. Low drug 
levels and thrombotic complications in high-risk atrial fibrillation patients treated 
with direct oral anticoagulants. J Thromb Haemost. 2018 May 1;16(5):842–8.  
62.  Mismetti P, Laporte S. New oral antithrombotics: a need for laboratory monitoring. 
For. J Thromb Haemost. 2010 Apr 1;8(4):621–6.  
63.  Boissier E, Genebrier S, Lakhal K, Nedelec-Gac F, Trossaërt M, Ternisien C, et al. 
Rivaroxaban and Apixaban Anti-Xa Measurements: Impact of Plasma Storage for 7 
Days at Room Temperature. Thromb Haemost. 2018 Aug 30;118(08):1488–90.  
64.  Douxfils J, Ageno W, Samama C-M, Lessire S, ten Cate H, Verhamme P, et al. 
Laboratory testing in patients treated with direct oral anticoagulants: a practical 
guide for clinicians. J Thromb Haemost. 2018 Feb 1;16(2):209–19.  
65.  Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the 
anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol. 
2014 Sep 16;64(11):1128–39.  
66.  Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the 
anticoagulant effects of the next generation of oral anticoagulants. J Thromb 
Haemost. 2013 Feb 1;11(2):245–52.  
67.  Yetman R, Barrett Y, Wang Z, Adamczyk R, Wang J, Ramacciotti E, et al. Apixaban 
pharmacodynamic activity in umbilical cord, paediatric, and adult plasma. Thromb 
Haemost. 2017 Nov 22;117(08):1518–27.  
68.  Studt J-D, Alberio L, Angelillo-Scherrer A, Asmis LM, Fontana P, Korte W, et al. 
Accuracy and consistency of anti-Xa activity measurement for determination of 
rivaroxaban plasma levels. J Thromb Haemost. 2017 Aug 1;15(8):1576–83.  
69.  Ignjatovic V. Thrombin Clotting Time. In: Methods in molecular biology (Clifton, NJ). 
2013. p. 131–8.  
70.  Wienen W, Stassen J-M, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo 
anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active 
prodrug, dabigatran etexilate. Thromb Haemost. 2007 Jul;98(1):155–62.  
71.  Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct 
thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. 
Thromb Res. 2003 Jul 15;109 Suppl 1:S9-15.  
72.  Stangier J, Clemens A. Pharmacology, Pharmacokinetics, and Pharmacodynamics of 
Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor. Clin Appl Thromb. 2009 Feb 
19;15(1_suppl):9S–16S.  
73.  Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct 
thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007 Sep;64(3):292–
303.  
74.  Ingelheim B. Relative bioavailability of dabigatran after administration of different 
application forms of a single oral dose of 150mg of dabigatran etixilate [Internet].  
75.  Golub AL, Frost RW, Betlach CJ, Gonzalez MA. Physiologic considerations in drug 
absorption from the gastrointestinal tract. J Allergy Clin Immunol. 1986 Oct 1;78(4 Pt 
2):689–94.  
76.  Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, et al. Pharmacokinetic 
Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy 
Volunteers and Patients Undergoing Total Hip Replacement. J Clin Pharmacol. 2005 
May;45(5):555–65.  
77.  Brighton T. Experimental and clinical pharmacology: New oral anticoagulant drugs - 
mechanisms of action. Aust Prescr. 2010 Apr 1;33(2):38–41.  
78.  Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The Metabolism and 
Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans. Drug Metab 
Dispos. 2008 Feb 1;36(2):386–99.  
79.  Stangier J. Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct 
Thrombin Inhibitor Dabigatran Etexilate. Clin Pharmacokinet. 2008;47(5):285–95.  
80.  Liesenfeld K-H, Lehr T, Dansirikul C, Reilly PA, Connolly SJ, Ezekowitz MD, et al. 
Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran 
etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial. J Thromb 
Haemost. 2011 Nov 1;9(11):2168–75.  
81.  Becattini C, Giustozzi M, Ranalli MG, Bogliari G, Cianella F, Verso M, et al. Variation of 
renal function over time is associated with major bleeding in patients treated with 
direct oral anticoagulants for atrial fibrillation. J Thromb Haemost. 2018 May 
1;16(5):833–41.  
82.  European Medicines Agency. CHMP assessment report for Pradaxa [Internet]. 2008.  
83.  DeWald TA, Becker RC. The pharmacology of novel oral anticoagulants. J Thromb 
Thrombolysis. 2014 Feb 17;37(2):217–33.  
84.  Terao T, Hisanaga E, Sai Y, Tamai I, Tsuji A. Active secretion of drugs from the small 
intestinal epithelium in rats by P-glycoprotein functioning as an absorption barrier. J 
Pharm Pharmacol. 1996 Oct;48(10):1083–9.  
85.  Avgil-Tsadok M, Jackevicius C, Essebag V, Eisenberg MJ, Rahme E, Behlouli H, et al. 
Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost. 2016 Jan 
22;115(01):152–60.  
86.  Perzborn E, Strassburger J, Wilmen A, Pohlmann J, Roehrig S, Schlemmer K-H, et al. In 
vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
direct Factor Xa inhibitor. J Thromb Haemost. 2005 Mar;3(3):514–21.  
87.  Gerotziafas, GT; Elalamy, I; Depasse, F; Perzborn, E; Samama M. In vitro inhibition of 
thrombin generation, after tissue factor pathway activation, by the oral, direct factor 
Xa inhibitor rivaroxaban. J Thromb Haemost. 2007;(5):886–8.  
88.  Moore KT, Krook MA, Vaidyanathan S, Sarich TC, Damaraju C V, Fields LE. Rivaroxaban 
Crushed Tablet Suspension Characteristics and Relative Bioavailability in Healthy 
Adults When Administered Orally or Via Nasogastric Tube. Clin Pharmacol Drug Dev. 
2014;3(4):321–7.  
89.  Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Effect of Food, an Antacid, and the H 2 
Antagonist Ranitidine on the Absorption of BAY 59-7939 (Rivaroxaban), an Oral, 
Direct Factor Xa Inhibitor, in Healthy Subjects. J Clin Pharmacol. 2006 May;46(5):549–
58.  
90.  Martin KA, Lee CR, Farrell TM, Moll S. Oral Anticoagulant Use After Bariatric Surgery: 
A Literature Review and Clinical Guidance. Am J Med. 2017 May;130(5):517–24.  
91.  Singh BN. Effects of Food on Clinical Pharmacokinetics. Clin Pharmacokinet. 1999 
Sep;37(3):213–55.  
92.  Kubitza D, Becka M, Zuehlsdorf M, Mueck W. Body Weight Has Limited Influence on 
the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 
59-7939) in Healthy Subjects. J Clin Pharmacol. 2007 Feb;47(2):218–26.  
93.  Weinz C, Schwarz T, Kubitza D, Mueck W, Lang D. Metabolism and Excretion of 
Rivaroxaban, an Oral, Direct Factor Xa Inhibitor, in Rats, Dogs, and Humans. Drug 
Metab Dispos. 2009 May 1;37(5):1056–64.  
94.  Kubitza D, Becka M, Mueck W, Halabi A, Maatouk H, Klause N, et al. Effects of renal 
impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, 
an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2010 Nov;70(5):703–12.  
95.  Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H, et al. Effect of hepatic 
impairment on the pharmacokinetics and pharmacodynamics of a single dose of 
rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013 Jul;76(1):89–
98.  
96.  Gnoth MJ, Buetehorn U, Muenster U, Schwarz T, Sandmann S. In Vitro and In Vivo P-
Glycoprotein Transport Characteristics of Rivaroxaban. J Pharmacol Exp Ther. 2011 Jul 
1;338(1):372–80.  
97.  Leslie EM, Deeley RG, Cole SPC. Multidrug resistance proteins: role of P-glycoprotein, 
MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol. 2005 May 
1;204(3):216–37.  
98.  Mueck W, Kubitza D, Becka M. Co-administration of rivaroxaban with drugs that 
share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin 
Pharmacol. 2013 Sep;76(3):455–66.  
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
99.  DeHaas KA. The Direct Oral Anticoagulants Apixaban, Rivaroxaban, and Edoxaban. Am 
Soc Clin Lab Sci. 2017 Jan 1;30(1):2–6.  
100.  Bonar R, Favaloro EJ, Mohammed S, Ahuja M, Pasalic L, Sioufi J, et al. The effect of the 
direct factor Xa inhibitors apixaban and rivaroxaban on haemostasis tests: a 
comprehensive assessment using in vitro and ex vivo samples. Pathology. 2016 
Jan;48(1):60–71.  
101.  Song Y, Chang M, Suzuki A, Frost RJA, Kelly A, LaCreta F, et al. Evaluation of Crushed 
Tablet for Oral Administration and the Effect of Food on Apixaban Pharmacokinetics 
in Healthy Adults. Clin Ther. 2016 Jul;38(7):1674–1685.e1.  
102.  Frost C, Nepal S, Wang J, Schuster A, Byon W, Boyd RA, et al. Safety, 
pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor 
Xa inhibitor, in healthy subjects. Br J Clin Pharmacol. 2013 Nov;76(5):776–86.  
103.  Wong PC, Pinto DJP, Zhang D. Preclinical discovery of apixaban, a direct and orally 
bioavailable factor Xa inhibitor. J Thromb Thrombolysis. 2011 May;31(4):478–92.  
104.  Upreti V V, Wang J, Barrett YC, Byon W, Boyd RA, Pursley J, et al. Effect of extremes of 
body weight on the pharmacokinetics, pharmacodynamics, safety and tolerability of 
apixaban in healthy subjects. Br J Clin Pharmacol. 2013 Dec;76(6):908–16.  
105.  Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, et al. Apixaban 
Metabolism and Pharmacokinetics after Oral Administration to Humans. Drug Metab 
Dispos. 2009 Jan 1;37(1):74–81.  
106.  Chang M, Yu Z, Shenker A, Wang J, Pursley J, Byon W, et al. Effect of renal impairment 
on the pharmacokinetics, pharmacodynamics, and safety of apixaban. J Clin 
Pharmacol. 2016 May;56(5):637–45.  
107.  Graff J, Harder S. Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors 
Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran 
Etexilate in Patients with Hepatic Impairment. Clin Pharmacokinet. 2013 Apr 
7;52(4):243–54.  
108.  Kubisz P, Stanciakova L, Dobrotova M, Samos M, Mokan M, Stasko J. Apixaban - 
Metabolism, Pharmacologic Properties and Drug Interactions. Curr Drug Metab. 2017 
Sep 6;18(7):609–21.  
109.  Frost CE, Byon W, Song Y, Wang J, Schuster AE, Boyd RA, et al. Effect of ketoconazole 
and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. 
Br J Clin Pharmacol. 2015 May;79(5):838–46.  
110.  Vakkalagadda B, Frost C, Byon W, Boyd RA, Wang J, Zhang D, et al. Effect of Rifampin 
on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa. Am J 
Cardiovasc Drugs. 2016 Apr 9;16(2):119–27.  
111.  Furugohri T, Isobe K, Honda Y, Kamisato-Matsumoto C, Sugiyama N, Nagahara T, et al. 
DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo 
pharmacological profiles. J Thromb Haemost. 2008 Jun;6(9):1542–9.  
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
112.  Stacy ZA, Call WB, Hartmann AP, Peters GL, Richter SK. Edoxaban: A Comprehensive 
Review of the Pharmacology and Clinical Data for the Management of Atrial 
Fibrillation and Venous Thromboembolism. Cardiol Ther. 2016 Jun;5(1):1–18.  
113.  Chen X, Liu D, Wu Y, Song H, Liu Y, Jiang J, et al. A single-dose study investigating the 
pharmacokinetics and pharmacodynamics of edoxaban at 30–90 mg in healthy 
Chinese volunteers. Xenobiotica. 2017 Jul 3;47(7):592–9.  
114.  Mendell J, Tachibana M, Shi M, Kunitada S. Effects of Food on the Pharmacokinetics 
of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers. J Clin 
Pharmacol. 2011 May;51(5):687–94.  
115.  Matsushima N, Lee F, Sato T, Weiss D, Mendell J. Bioavailability and Safety of the 
Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy Subjects. Clin 
Pharmacol Drug Dev. 2013 Oct;2(4):358–66.  
116.  Parasrampuria DA, Kanamaru T, Connor A, Wilding I, Ogata K, Shimoto Y, et al. 
Evaluation of regional gastrointestinal absorption of edoxaban using the enterion 
capsule. J Clin Pharmacol. 2015 Nov;55(11):1286–92.  
117.  Parasrampuria DA, Truitt KE. Pharmacokinetics and Pharmacodynamics of Edoxaban, 
a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin 
Pharmacokinet. 2016;55(6):641–55.  
118.  Bathala MS, Masumoto H, Oguma T, He L, Lowrie C, Mendell J. Pharmacokinetics, 
Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa 
Inhibitor, in Humans. Drug Metab Dispos. 2012 Dec 1;40(12):2250–5.  
119.  Cada DJ, Baker DE, Ingram K. Edoxaban. Hosp Pharm. 2015 Jul;50(7):619–34.  
120.  Plitt A, Giugliano RP. Edoxaban: Review of Pharmacology and Key Phase I to III Clinical 
Trials. J Cardiovasc Pharmacol Ther. 2014 Sep 7;19(5):409–16.  
121.  Mendell J, Johnson L, Chen S. An open-label, phase 1 study to evaluate the effects of 
hepatic impairment on edoxaban pharmacokinetics and pharmacodynamics. J Clin 
Pharmacol. 2015 Dec;55(12):1395–405.  
122.  Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 
European Heart Rhythm Association Practical Guide on the use of non-vitamin K 
antagonist oral anticoagulants in patients with atrial fibrillation.  
123.  Voukalis C, Lip GYH, Shantsila E. Drug-drug interactions of non-vitamin K oral 
anticoagulants. Expert Opin Drug Metab Toxicol. 2016 Dec 26;12(12):1445–61.  
124.  Mendell J, Chen S, He L, Desai M, Parasramupria DA. The Effect of Rifampin on the 
Pharmacokinetics of Edoxaban in Healthy Adults. Clin Drug Investig. 2015 Jul 
12;35(7):447–53.  
125.  Mendell J, Lee F, Chen S, Worland V, Shi M, Samama MM. The Effects of the 
Antiplatelet Agents, Aspirin and Naproxen, on Pharmacokinetics and 
Pharmacodynamics of the Anticoagulant Edoxaban, a Direct Factor Xa Inhibitor. J 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
Cardiovasc Pharmacol. 2013 Aug;62(2):212–21.  
126.  Maddison J, Somogyi AA, Jensen BP, James HM, Gentgall M, Rolan PE. The 
pharmacokinetics and pharmacodynamics of single dose (R)-and (S)-warfarin 
administered separately and together: relationship to VKORC1 genotype. 2012;  
127.  Yin T, Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 — 
Rationale and perspectives. Thromb Res. 2007 Jan;120(1):1–10.  
128.  Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and 
excretion. Xenobiotica. 2001 Jan 22;31(8–9):469–97.  
129.  Johnson JA, Gong L, Whirl-Carrillo M, Gage BF, Scott SA, Stein CM, et al. Clinical 
Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 
genotypes and warfarin dosing. Clin Pharmacol Ther. 2011 Oct;90(4):625–9.  
130.  Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, et al. A 
Randomized Trial of Genotype-Guided Dosing of Warfarin. N Engl J Med. 2013 Dec 
12;369(24):2294–303.  
131.  Kimmel SE, French B, Kasner SE, Johnson JA, Anderson JL, Gage BF, et al. A 
Pharmacogenetic versus a Clinical Algorithm for Warfarin Dosing. N Engl J Med. 2013 
Dec 12;369(24):2283–93.  
132.  Lu G, Hollenbach SJ, Baker DC, Tan S, Hutchaleelaha A, Curnutte JT, et al. Preclinical 
safety and efficacy of andexanet alfa in animal models. J Thromb Haemost. 2017 Sep 
1;15(9):1747–56.  
133.  Heo Y-A. Andexanet Alfa: First Global Approval. Drugs. 2018 Jul 20;78(10):1049–55.  
134.  Weitz JI, Harenberg J. New developments in anticoagulants: Past, present and future. 
Thromb Haemost. 2017 Nov 11;117(07):1283–8.  
135.  Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 
European Heart Rhythm Association Practical Guide on the use of non-vitamin K 
antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018 Apr 
21;39(16):1330–93.  
136.  Bristol-Myers. Squibb. Eliquis (apixaban) 2.5 and 5 mg Tablets. [Internet]. 2014.  
137.  Reinecke H, Jürgensmeyer S, Engelbertz C, Gerss J, Kirchhof P, Breithardt G, et al. 
Design and rationale of a randomised controlled trial comparing apixaban to 
phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the 
AXADIA-AFNET 8 study. BMJ Open. 2018 Sep 10;8(9):e022690.  
138.  Stanton BE, Barasch NS, Tellor KB. Comparison of the Safety and Effectiveness of 
Apixaban versus Warfarin in Patients with Severe Renal Impairment. Pharmacother J 
Hum Pharmacol Drug Ther. 2017 Apr;37(4):412–9.  
139.  Martin JL, Esmaeili H, Manuel RC, Petrini M, Wiebe S, Maas H. 
Pharmacokinetics/Pharmacodynamics of Dabigatran 75 mg Twice Daily in Patients 
With Nonvalvular Atrial Fibrillation and Severely Impaired Renal Function. J 
Ac
ce
pte
d M
an
us
cri
pt
 
 
 
 
Cardiovasc Pharmacol Ther. 2018 Sep 25;23(5):399–406.  
140.  Sherwood MW, Nessel CC, Hellkamp AS, Mahaffey KW, Piccini JP, Suh E-Y, et al. 
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With Rivaroxaban 
or Warfarin. J Am Coll Cardiol. 2015 Dec 1;66(21):2271–81.  
141.  Hellenbart E, Faulkenberg K, Finks S. Evaluation of bleeding in patients receiving 
direct oral anticoagulants. Vasc Health Risk Manag. 2017 Aug;Volume 13:325–42.  
142.  Granger CB, Alexander JH, McMurray JJV, Lopes RD, Hylek EM, Hanna M, et al. 
Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med. 2011 Sep 
15;365(11):981–92.  
143.  Di Minno A, Frigerio B, Spadarella G, Ravani A, Sansaro D, Amato M, et al. Old and 
new oral anticoagulants: Food, herbal medicines and drug interactions. Blood Rev. 
2017 Jul;31(4):193–203.  
144.  Nutescu EA, Shapiro NL, Ibrahim S, West P. Warfarin and its interactions with foods, 
herbs and other dietary supplements. Expert Opin Drug Saf. 2006 May 13;5(3):433–
51.  
145.  Vranckx P, Valgimigli M, Heidbuchel H. The Significance of Drug-Drug and Drug-Food 
Interactions of Oral Anticoagulation. Arrhythmia Electrophysiol Rev. 2018 
Mar;7(1):55–61.  
146.  Tiaden JD, Wenzel E, Berthold HK, Müller-Oerlinghausen B. Adverse Reactions to 
Anticoagulants and to Antiplatelet Drugs Recorded by the German Spontaneous 
Reporting System. Semin Thromb Hemost. 2005 Aug;31(04):371–80.  
 
